BAY 3771249 Clinical Trials (2026): 1 Studies for Advanced/Metastatic Colorectal Adenocarcinoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 BAY 3771249 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Advanced/Metastatic Colorectal Adenocarcinoma) and 130 total planned enrollment. 1 BAY 3771249 clinical trial is actively recruiting at 1 U.S. site across 1 state. Most recent activity: NCT07535112 (Jul 2030).
Where to Participate: All BAY 3771249 Trial Sites in the U.S. (1 site across 1 state)
Every actively recruiting BAY 3771249trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| TX | NEXT Dallas - Oncology Department | Irving75039 | NCT07535112 | Map |
BAY 3771249 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting BAY 3771249 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07535112 | A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation | P1 | Advanced/Metastatic Colorectal Adenocarcinoma | 130 | Apr 2026 |
All BAY 3771249 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07535112 | A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation | P1 | recruiting | 130 | Bayer | Apr 2026 |
BAY 3771249 clinical trials: frequently asked questions
- How many BAY 3771249 clinical trials are there?
- 1 BAY 3771249 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are BAY 3771249 clinical trials recruiting in 2026?
- Yes — 1 BAY 3771249 trial is actively recruiting in 2026, with 1 U.S. site across 1 state. See the recruiting trials and the per-state site list further down this page.
- What conditions is BAY 3771249 being studied for?
- BAY 3771249 is being studied for Advanced/Metastatic Colorectal Adenocarcinoma. The trials are grouped by indication on this page.
- What phase is BAY 3771249 in?
- BAY 3771249 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors BAY 3771249 clinical trials?
- The lead sponsor across the most BAY 3771249 trials is Bayer. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming BAY 3771249as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: